Company: CNTB
Filing Date: 2025-04-01
Form Type: 8-K
Source: 0001835268-25-000019
Chunk: 0

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-04-01
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01 Regulation FD Disclosure.

On April 1, 2025, Connect Biopharma Holdings Limited (the “ Company”) issued a press release announcing positive feedback from its Type C meeting with the U. S. Food and Drug Administration (“ FDA”), Division of Pulmonology, Allergy, and Critical Care, in the Office of Immunology and Inflammation (the “ Type C Meeting”). A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.